ImmunoGen – T-DM1 Updates

ImmunoGen, Inc. (NASDAQ:IMGN). Last Market Price: 11.06, Change: +0.80, % Change: (7.80%). Shares trade in the range of 10.68 – 11.40 dollars. It has a market capitalization of 844.75M dollars, making it a Small Cap Stock and has 76.38M outstanding shares. The company has a beta of 1.78, indicating, the stock to be more volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.85. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 77%. The company has a 52 week high of $ 16.20 and a 52 week low of $ 5.51. Average volumes of shares traded daily are 626,443. Volume traded in the last session was at 1,290,000, 2.06 times the average volume.

• T-DM1 shows improvement in progression-free survival

• T-DM1 Significantly Improved Progression-Free Survival Compared to Standard of Care for Previously Untreated HER2-Positive Metastatic Breast Cancer

• Company announced findings from the first randomized clinical trial conducted with T-DM1. T-DM1 consists of ImmunoGen’s DM1 cancer cell-killing agent attached to the HER2-targeting antibody

For Q2 (Jun ’11), It had a Net profit margin of -248.27%, an Operating margin of -248.95%. Other Key stats and ratios are : Return on average assets of -35.99%, Return on average equity of -63.26%. The organization has an employee strength of 248

Consensus Recommendation is a Outperform.

Estimate for sales for the Year Ending Jun-12 show a mean of 25.74 million dollars, an estimate high of 41.89 million dollars and an estimate low of 16.19 million dollars. A year ago the figures stood at 25.08 million dollars.

Estimate for sales for the Year Ending Jun-13 show a mean of 41.41 million dollars, an estimate high of 62.30 million dollars and an estimate low of 25.50 million dollars. A year ago the figures stood at 57.77 million dollars.

Estimate for EPS for the Year Ending Jun-12 show a mean of -0.89 dollars, an estimate high of -0.76 dollars and an estimate low of -0.99 dollars. A year ago the figures stood at -0.83 dollars.

Estimate for EPS for the Year Ending Jun-13 show a mean of -0.71 dollars, an estimate high of -0.27 dollars and an estimate low of -0.95 dollars. A year ago the figures stood at -0.47 dollars.

Sales for Quarter Ending Jun-11 was estimated at 4.40 million dollars, however the actual sales figure stood at 6.51 million dollars, 2.1 million dollars more than estimates.

Sales for Quarter Ending Mar-11 was estimated at 4.19 million dollars, however the actual sales figure stood at 5.21 million dollars, 1.02 million dollars more than estimates.

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.